A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Fiche publication
Date publication
juin 2015
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEMARCHI Martin
Tous les auteurs :
Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P
Lien Pubmed
Résumé
Masitinib is a selective oral tyrosine-kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
Mots clés
ACOX1, PDAC, genetic biomarker, pain, pancreatic cancer, tyrosine–kinase inhibitor
Référence
Ann Oncol. 2015 Jun;26(6):1194-1200